Principia Biopharma Inc. (PRNB)
| Market Cap | 3.33B |
| Revenue (ttm) | 50.00M |
| Net Income (ttm) | -68.91M |
| Shares Out | 33.09M |
| EPS (ttm) | -2.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | Sep 28, 2020 |
| Last Price | $100.05 |
| Previous Close | $100.05 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | - |
| Day's Range | 99.95 - 100.37 |
| Day's Volume | 0 |
| 52-Week Range | 25.35 - 101.89 |
News
Sanofi announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), applicable to Sanofi’s proposed acquisition of Princi...
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune me...
SAN DIEGO, Sept. 12, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc.
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: Principia Biopharma Inc.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Principia (PRNB) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
NEW YORK, Aug. 17, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Principia Biopharma Inc.
New York, New York--(Newsfile Corp. - August 17, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Principia Biopharma Inc.
NEW YORK, Aug. 17, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in Ne...
This isn't the pharmaceutical giant's only recent ride at the acquisition rodeo.
TOKYO--(BUSINESS WIRE)--Financial executives at Oita Chuo Pacific Management have commented on Sanofi agreeing to acquire U.S. Principia Biopharma for $3.4 billion.
Principia Biopharma Inc. (NASDAQ: PRNB) shares jumped to start out the week after it was announced that it would be acquired by Sanofi (NASDAQ: SNY).
Sanofi (SNY) offers $3.68 billion to buy Principia Biopharma. The deal is likely to strengthen the company's core R&D areas of autoimmune and allergic diseases.
Sanofi is expanding efforts to combat MS and other autoimmune diseases by announcing a $3.68 billion acquisition of partner Principia Biopharma. The post Sanofi To Acquire Partner Principia Bi...
Sanofi S.A. (EPA: SAN) expressed plans of acquiring Principia Biopharma Inc.
Sanofi to Buy Principia Biopharma in $3.4 Billion Deal
Aug.17 -- Sanofi has agreed to acquire Principia Biopharma Inc.
Sanofi SA (NASDAQ: SNY) will acquire Principia Biopharma Inc (NASDAQ: PRNB) for $3.68 billion in cash, the two companies announced Monday.
French health care company Sanofi has agreed to buy U.S. company Principia Biopharma for around $3.7 billion, the companies said on Monday, strengthening Sanofi's presence in research and deve...
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Dosing of Patient Will Trigger $50 Million Milestone Payment Dosing of Patient Will Trigger $50 Million Milestone Payment
Clear dose-response combined with decreased daily corticosteroid usage
Oral BTK inhibitor reaches primary endpoint in 50 percent of patients treated > 12 weeks; demonstrates fast onset and durable responses
SOUTH SAN FRANCISCO, Calif., May 26, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing treatments for immune-medi...
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Principia Biopharma Inc. (PRNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Company expands focus on immune-mediated diseases and suspends FGFR program
Company’s lead candidate PRN1008 receives generic name -- rilzabrutinib
Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results in second half of 2021 Accelerated enrollment of company’s Phase 3 pivotal trial anticipating final results...
Principia Biopharma stock has rocketed 31% this week amid enthusiasm for its technology, BTK inhibition — highlighted by notable moves from pharmaceutical giants Merck and Sanofi.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immun...
Principia Biopharma Inc. (PRNB) delivered earnings and revenue surprises of -9.41% and -100.00%, respectively, for the quarter ended September 2019.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immun...
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immun...
Preliminary results from trial have been accepted as an oral presentation at upcoming American Society of Hematology Annual Meeting Preliminary results from trial have been accepted as an oral...
Consistent efficacy and safety profile for pemphigus patients observed
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral thera...
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral thera...
Undercovered stock with strong potential in developing next-generation BTK inhibitors.
About PRNB
Principia Biopharma, a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company is developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating mult... [Read more...]
| Industry Biotechnology | IPO Date Sep 14, 2018 |
| CEO Martin Babler | Employees 124 |
| Stock Exchange NASDAQ | Ticker Symbol PRNB |